Roivant Sciences Announces Change to its Board of Directors
February 21 2023 - 8:32PM
Roivant Sciences (Nasdaq: ROIV) today announced that its founder
Vivek Ramaswamy has stepped down from the company’s board of
directors to focus on his U.S. presidential campaign.
Vivek founded Roivant in 2014 with the vision of
revolutionizing drug development. Over the past decade, the FDA has
granted six FDA approvals for medicines developed at Vants launched
by Roivant, including VTAMA, approved for plaque psoriasis in
2022.
In January 2021, Vivek transitioned out of his
day-to-day role as CEO of the company. He served as Roivant’s
Chairman until February 20, 2023.
“On behalf of the entire company, I would like
to extend our deepest gratitude to Vivek for his vision and
leadership over the years. Vivek started Roivant in 2014 to
transform the way that meaningful therapies were developed and
commercialized, and that mission is still very much a part of
Roivant’s DNA today. We are grateful for Vivek’s contributions to
the board and to the organization, and we wish him well in his
future endeavors,” said Matt Gline, CEO of Roivant.
About Roivant Sciences
Roivant's mission is to improve the delivery of
healthcare to patients by treating every inefficiency as an
opportunity. Roivant develops transformative medicines faster by
building technologies and developing talent in creative ways,
leveraging the Roivant platform to launch "Vants" – nimble and
focused biopharmaceutical and health technology companies.
Roivant Sciences Forward-Looking
Statements
This press release contains forward-looking
statements. Statements in this press release may include statements
that are not historical facts and are considered forward-looking
within the meaning of Section 27A of the Securities Act of 1933, as
amended (the "Securities Act"), and Section 21E of the Securities
Exchange Act of 1934, as amended (the "Exchange Act"), which are
usually identified by the use of words such as "anticipate,"
"believe," "continue," "could," "estimate," "expect," "intends,"
"may," "might," "plan," "possible," "potential," "predict,"
"project," "should," "would" and variations of such words or
similar expressions. Such words may identify forward-looking
statements, but the absence of these words does not mean that a
statement is not forward-looking. We intend these forward-looking
statements to be covered by the safe harbor provisions for
forward-looking statements contained in Section 27A of the
Securities Act and Section 21E of the Exchange Act.
Our forward-looking statements include, but are
not limited to, statements regarding the terms and completion of
the proposed public offering, our or our management team’s
expectations, hopes, beliefs, intentions or strategies regarding
the future, and statements that are not historical facts, including
statements about the clinical and therapeutic potential of our
products and product candidates, the availability and success of
topline results from our ongoing clinical trials and any commercial
potential of our products and product candidates. In addition, any
statements that refer to projections, forecasts or other
characterizations of future events or circumstances, including any
underlying assumptions, are forward-looking statements.
Although we believe that our plans, intentions,
expectations and strategies as reflected in or suggested by those
forward-looking statements are reasonable, we can give no assurance
that the plans, intentions, expectations or strategies will be
attained or achieved. Furthermore, actual results may differ
materially from those described in the forward-looking statements
and will be affected by a number of risks, uncertainties and
assumptions, including, but not limited to, those risks set forth
in the Risk Factors section of our filings with the U.S. Securities
and Exchange Commission. Moreover, we operate in a very competitive
and rapidly changing environment in which new risks emerge from
time to time. These forward-looking statements are based upon the
current expectations and beliefs of our management as of the date
of this press release, and are subject to certain risks and
uncertainties that could cause actual results to differ materially
from those described in the forward-looking statements. Except as
required by applicable law, we assume no obligation to update
publicly any forward-looking statements, whether as a result of new
information, future events or otherwise.
Contacts:
Investors
Roivant Investor Relationsir@roivant.com
Media
Stephanie LeeRoivant
Sciencesstephanie.lee@roivant.com
Roivant Sciences (NASDAQ:ROIV)
Historical Stock Chart
From Sep 2024 to Oct 2024
Roivant Sciences (NASDAQ:ROIV)
Historical Stock Chart
From Oct 2023 to Oct 2024